Is tirzepatide more effective than semaglutide?

On average, yes — published trials show tirzepatide produces greater weight loss at maximum dose. But effectiveness varies by person, and semaglutide remains highly effective for most patients. Your clinician chooses based on your health, goals, side effects, and access.

Can I switch from one to the other?

Yes, under clinician guidance. Switching typically involves stopping the first medication and re-titrating from a low starting dose of the second to manage gastrointestinal side effects.

How long do I take them?

Both are designed for long-term use; stopping typically results in weight regain as appetite returns toward baseline. Many patients maintain results on a lower maintenance dose with clinician guidance.

Semaglutide vs. Tirzepatide: How They Differ and How to Choose

A plain-English comparison of the two leading GLP-1 weight-loss medications — mechanism, expected weight loss, side effects, dosing, cost, and how a clinician decides which one is right for you.

Semaglutide and tirzepatide are the two most prescribed weight-management medications in the United States. Both quiet appetite, slow gastric emptying, and improve metabolic markers — but they work through slightly different receptors and produce different magnitudes of weight loss in clinical trials.

The short answer

Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP agonist — it acts on two appetite-regulating receptors instead of one. In head-to-head and indirect comparisons, tirzepatide tends to produce more weight loss on average, but semaglutide remains highly effective and is appropriate for most patients starting a weight-management program.

How they work

Both medications mimic gut hormones (incretins) that are released after a meal. They signal your brain that you're full, slow digestion so you feel full longer, and improve insulin sensitivity. Tirzepatide additionally activates GIP, a related incretin that further enhances appetite suppression and metabolic effects.

Expected weight loss

In published phase 3 trials, semaglutide 2.4 mg weekly produced average weight loss of about 15% of body weight over 68 weeks. Tirzepatide 10–15 mg weekly produced average weight loss of about 20–22% over a similar duration. Individual results vary substantially with dose, adherence, lifestyle, and biology.

Side effects

The most common side effects of both medications are gastrointestinal: nausea, constipation, diarrhea, and reflux, usually most pronounced during dose increases and improving with time. Slow titration, hydration, smaller meals, and adequate fiber and protein reduce these effects substantially.

Who should not take them

Neither medication is appropriate if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a history of pancreatitis, or are pregnant, breastfeeding, or trying to conceive. Your clinician screens for these and additional contraindications during intake.

Compounded vs brand

Brand-name semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) are FDA-approved. Compounded versions of the same active ingredients are prepared by FDA-registered 503A pharmacies and are not FDA-approved as finished products. Your clinician will discuss which option fits your situation, insurance status, and risk tolerance.